Sign up here to receive news updates via email.
-
April 3, 2017 |
Media, Press Releases
BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Multiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel
read moreBOSTON, April 3, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster presentations showing promising preclinical data. This data reflects the impact of BERG’s leading product candidate, BPM 31510, to augment immune responses and potentially improve outcomes of patients suffering from glioblastoma multiforme (GBM), pancreatic…
-
March 27, 2017 |
Media, Press Releases
New Data Published in Nature Medicine from Joslin Diabetes Center Demonstrates the Importance of Interrogating Human Biology
read moreBOSTON, March 27, 2017— BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that the company’s Interrogative Biology® Platform contributed to the discovery of new data using a cold-induced model to promote thermogenesis and facilitate brown fat metabolism. Joslin Diabetes Center led the investigation with BERG providing its Interrogative Biology® platform…
-
February 15, 2017 |
Media, Press Releases
BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)
read moreBOSTON, Feb. 15, 2017 — BERG LLC, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase I/II monotherapy clinical trial for its drug candidate BPM 31510-IV for the potential treatment of glioblastoma multiforme. The compound was guided in development by BERG’s unique AI-based Interrogative Biology® platform that combines…
-
January 12, 2017 |
Media, Press Releases
BERG Enters into Multi-Year Agreement with BD for Next-Generation Analytics in Healthcare IT
read moreLeading Health Companies Combine Health IT Expertise to Advance Patient Health Outcomes BOSTON, Jan. 12, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, announced a multi-year agreement between BERG Analytics, a division of BERG, and BD’s MedMined™ solution. This new collaboration will leverage the combined healthcare IT expertise of BD…
-
November 14, 2016 |
Media, Press Releases
BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting
read moreBERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting BERG Interrogative Biology® Platform Identifies Potential Contributor to LRRK2-mediated Cell Death in Parkinson’s Disease BOSTON, November 14, 2016 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today unveiled data from a recent study that clarified…
-
November 1, 2016 |
Media, Press Releases
BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016
read moreBERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016 Leading players at the forefront of healthcare innovation will discuss how emerging technologies are delivering on the promise of precision medicine BOSTON – October 31, 2016 — BERG, a biopharmaceutical company uncovering health…
